Age- and gender-related differences in SVR and relapse following treatment of HCV genotype 3 (G3) infection with Peginterferon alfa-2b (peg2b)/Ribavirin (RBV) in real-life
S Mauss, D Hüppe, E Zehnter, MP Manns, G Teuber, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, A Heuser, M Bilzer · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: Because of the current lack of direct antiviral drugs, improvement of HCV G3 treatment can be achieved only by optimization of dual therapy. Preliminary data suggest lower SVR rates for G3 infected elder patients. We therefore aimed to identify the contributing factors. Methods: Within a multicenter observational study in Germany 1328 of 4061 patients with chronic hepatitis C were infected with G3. Of these, 1090 patients had documented treatment with Peg-IFNα-2b 1.5µg/kg/week plus RBV (800–1200mg/day) for a median of 24 weeks and were included in this retrospective analysis. Patients were stratified…
